From July 24 to 25, the 2025 Beijing Conference of the Boao Forum for Asia Global Health Forum, co-hosted by the People's Government of Beijing Municipality and the Boao Forum for Asia, was held in Beijing with the theme "A New Future for the Health Industry Driven by Innovation". The forum attracted more than 300 government officials, heads of international organizations, entrepreneurs, scholars, diplomatic envoys and representatives of Chinese and foreign media from 34 countries and regions to discuss new ideas for empowering the development of global health undertakings through technological and scientific innovation.
The forum covered a wide range of major issues in the field of health, in-depth discussions on the development trends of strategic emerging industries such as biomedicine and artificial intelligence, as well as new challenges in the health field including universal health coverage, global health governance, and climate change and health.
As an enterprise with original patented technologies in the field of sequencing systems, Cygnus Bio was invited to attend this grand event and presented its GS200 Sequencing System at the achievement exhibition. The GS200 Sequencing System is compatible with various throughput specifications ranging from 25M to 400M, and features an ultra-fast sequencing speed of 4 hours, which significantly improves the efficiency and applicability of gene sequencing. With distinct advantages such as fast detection speed, high data quality and low operating cost, the GS200 Sequencing System is widely used in fields such as pathogen genome sequencing and infectious disease traceability, providing strong technical support for disease control work.
Based on its profound technical accumulation, Cygnus Bio has successfully launched a variety of sequencing systems, including the GS100 and Product Line P (GP1000 and GP1000X). Among them, the GS100 and GS200 Sequencing Systems have obtained the EU CE-IVDR certification; the Product Line P gene sequencing platform can achieve a single-run sequencing throughput coverage of 0.3Tb to 40Tb.
In the future, Cygnus Bio will continue to deepen technological innovation, continuously improve the performance and user experience of sequencers, and promote the inclusive application of gene sequencing technology. At the same time, the company will continuously improve its product matrix and service system to meet the diverse needs of customers, contribute technological strength to improving public health levels, and inject technological momentum into the construction of a healthy public.
